DOP2023000107A - Compuesto de heteroarilcarboxamida - Google Patents
Compuesto de heteroarilcarboxamidaInfo
- Publication number
- DOP2023000107A DOP2023000107A DO2023000107A DO2023000107A DOP2023000107A DO P2023000107 A DOP2023000107 A DO P2023000107A DO 2023000107 A DO2023000107 A DO 2023000107A DO 2023000107 A DO2023000107 A DO 2023000107A DO P2023000107 A DOP2023000107 A DO P2023000107A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibody
- cancer
- compound
- treatment
- activation
- Prior art date
Links
- -1 CARBOXAMIDE COMPOUND Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000009175 antibody therapy Methods 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005931 immune cell recruitment Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1. Los presentes inventores han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1, y han confirmado que un compuesto de heteroarilcarboxamida tiene un efecto inhibidor ¿ de DGK (DGKzeta), lo que conduce a la finalización de la presente invención. El compuesto de heteroarilcarboxamida de la presente invención tiene un efecto inhibidor ¿ de DGK y puede usarse como un agente terapéutico para el tratamiento de cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020197899 | 2020-11-30 | ||
| PCT/JP2021/043540 WO2022114164A1 (ja) | 2020-11-30 | 2021-11-29 | ヘテロアリールカルボキシアミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000107A true DOP2023000107A (es) | 2023-07-16 |
Family
ID=81754515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000107A DOP2023000107A (es) | 2020-11-30 | 2023-05-29 | Compuesto de heteroarilcarboxamida |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20240043403A1 (es) |
| EP (1) | EP4253373A4 (es) |
| JP (1) | JP7397452B2 (es) |
| KR (1) | KR20230116838A (es) |
| CN (1) | CN116528864A (es) |
| AR (1) | AR124172A1 (es) |
| AU (1) | AU2021389180A1 (es) |
| CA (1) | CA3203285A1 (es) |
| CL (1) | CL2023001534A1 (es) |
| CO (1) | CO2023008271A2 (es) |
| CR (1) | CR20230415A (es) |
| DO (1) | DOP2023000107A (es) |
| EC (1) | ECSP23048974A (es) |
| IL (1) | IL303209A (es) |
| MX (1) | MX2023006318A (es) |
| PE (1) | PE20231986A1 (es) |
| TW (1) | TW202229256A (es) |
| WO (1) | WO2022114164A1 (es) |
| ZA (1) | ZA202305845B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CN116528864A (zh) * | 2020-11-30 | 2023-08-01 | 安斯泰来制药株式会社 | 杂芳基甲酰胺化合物 |
| EP4539848A1 (en) | 2022-06-20 | 2025-04-23 | Astellas Pharma Inc. | Methods for treating patients with locally advanced and/or metastatic solid tumors using a dgk zeta inhibitor |
| US20240217989A1 (en) * | 2022-11-18 | 2024-07-04 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
| WO2024151346A1 (en) * | 2023-01-12 | 2024-07-18 | Incyte Corporation | Heteroaryl fluoroalkenes as dgk inhibitors |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
| WO2024199387A1 (zh) * | 2023-03-30 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| WO2024208198A1 (zh) * | 2023-04-06 | 2024-10-10 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
| WO2025067360A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 一种DGKzeta拮抗剂及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| ZA200707125B (en) | 2005-01-25 | 2008-11-26 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| KR20090004976A (ko) * | 2006-04-19 | 2009-01-12 | 아스테라스 세이야쿠 가부시키가이샤 | 아졸카르복사미드 유도체 |
| US9206142B2 (en) * | 2006-10-31 | 2015-12-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
| WO2019046944A1 (en) | 2017-09-06 | 2019-03-14 | Propellon Therapeutics Inc. | INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN |
| BR112020026681A2 (pt) | 2018-06-27 | 2021-04-06 | Bristol-Myers Squibb Company | Compostos naftiridinona substituídos úteis como ativadores de célula t |
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| MA59379B1 (fr) | 2020-04-24 | 2025-04-30 | Bayer Aktiengesellschaft | Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire |
| CN116528864A (zh) | 2020-11-30 | 2023-08-01 | 安斯泰来制药株式会社 | 杂芳基甲酰胺化合物 |
-
2021
- 2021-11-29 CN CN202180080083.8A patent/CN116528864A/zh active Pending
- 2021-11-29 US US18/254,829 patent/US20240043403A1/en active Pending
- 2021-11-29 AU AU2021389180A patent/AU2021389180A1/en active Pending
- 2021-11-29 CR CR20230415A patent/CR20230415A/es unknown
- 2021-11-29 CA CA3203285A patent/CA3203285A1/en active Pending
- 2021-11-29 IL IL303209A patent/IL303209A/en unknown
- 2021-11-29 JP JP2022565480A patent/JP7397452B2/ja active Active
- 2021-11-29 TW TW110144382A patent/TW202229256A/zh unknown
- 2021-11-29 AR ARP210103290A patent/AR124172A1/es unknown
- 2021-11-29 KR KR1020237021502A patent/KR20230116838A/ko active Pending
- 2021-11-29 WO PCT/JP2021/043540 patent/WO2022114164A1/ja not_active Application Discontinuation
- 2021-11-29 PE PE2023001705A patent/PE20231986A1/es unknown
- 2021-11-29 MX MX2023006318A patent/MX2023006318A/es unknown
- 2021-11-29 EP EP21898136.3A patent/EP4253373A4/en active Pending
-
2023
- 2023-05-29 CL CL2023001534A patent/CL2023001534A1/es unknown
- 2023-05-29 DO DO2023000107A patent/DOP2023000107A/es unknown
- 2023-05-31 ZA ZA2023/05845A patent/ZA202305845B/en unknown
- 2023-06-23 CO CONC2023/0008271A patent/CO2023008271A2/es unknown
- 2023-06-29 EC ECSENADI202348974A patent/ECSP23048974A/es unknown
- 2023-11-28 US US18/521,400 patent/US12077519B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202229256A (zh) | 2022-08-01 |
| CO2023008271A2 (es) | 2023-07-21 |
| US12077519B2 (en) | 2024-09-03 |
| IL303209A (en) | 2023-07-01 |
| AR124172A1 (es) | 2023-02-22 |
| AU2021389180A9 (en) | 2024-06-13 |
| MX2023006318A (es) | 2023-06-14 |
| CA3203285A1 (en) | 2022-06-02 |
| KR20230116838A (ko) | 2023-08-04 |
| CL2023001534A1 (es) | 2023-11-10 |
| ECSP23048974A (es) | 2023-07-31 |
| AU2021389180A1 (en) | 2023-06-29 |
| WO2022114164A1 (ja) | 2022-06-02 |
| EP4253373A4 (en) | 2024-11-13 |
| US20240043403A1 (en) | 2024-02-08 |
| ZA202305845B (en) | 2024-09-25 |
| EP4253373A1 (en) | 2023-10-04 |
| JP7397452B2 (ja) | 2023-12-13 |
| US20240101532A1 (en) | 2024-03-28 |
| PE20231986A1 (es) | 2023-12-12 |
| CR20230415A (es) | 2023-09-08 |
| JPWO2022114164A1 (es) | 2022-06-02 |
| CN116528864A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000107A (es) | Compuesto de heteroarilcarboxamida | |
| DOP2022000137A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| CL2019003589A1 (es) | Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer. | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2021000299A (es) | Preparados combinados para el tratamiento contra el cancer o infecciones. | |
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. | |
| MX2018001673A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
| AR096673A1 (es) | Métodos para aumentar la eficacia de terapias médicas | |
| MX2017009863A (es) | Agente preventivo y/o terapeutico de enfermedad inmune. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. |